Genetic Technologies (GENE) Competitors

Genetic Technologies (NASDAQ:GENE) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.

Does the MarketBeat Community prefer GENE or CTXR?

Citius Pharmaceuticals received 53 more outperform votes than Genetic Technologies when rated by MarketBeat users. Likewise, 62.21% of users gave Citius Pharmaceuticals an outperform vote while only 55.33% of users gave Genetic Technologies an outperform vote.

Company	Underperform	Outperform
Genetic Technologies	Outperform Votes 161 55.33%	Underperform Votes 130 44.67%
Citius Pharmaceuticals	Outperform Votes 214 62.21%	Underperform Votes 130 37.79%

Which has more risk & volatility, GENE or CTXR?

Genetic Technologies has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Which has stronger valuation and earnings, GENE or CTXR?

Genetic Technologies has higher revenue and earnings than Citius Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genetic Technologies	$7.66M	0.44	-$7.88M	N/A	N/A
Citius Pharmaceuticals	N/A	N/A	-$39.14M	N/A	N/A

Does the media refer more to GENE or CTXR?

In the previous week, Genetic Technologies had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 10 mentions for Genetic Technologies and 8 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.49 beat Genetic Technologies' score of -0.06 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genetic Technologies	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is GENE or CTXR more profitable?

Genetic Technologies' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genetic Technologies	N/A	N/A	N/A
Citius Pharmaceuticals	N/A	-51.69%	-37.60%

Do insiders & institutionals believe in GENE or CTXR?

0.6% of Genetic Technologies shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 6.5% of Genetic Technologies shares are owned by insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts rate GENE or CTXR?

Citius Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 5,823.91%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Genetic Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genetic Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Citius Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Citius Pharmaceuticals beats Genetic Technologies on 9 of the 15 factors compared between the two stocks.